Examination of Vitamin-D Levels in Patients with Schizophrenia and Schizoaffective Disorder: A Retrospective Study

Year 2024, , 827 - 831, 31.12.2024

Selin Balki Tekin , Ayşe Nur İnci Kenar , Ayşenur Tecim Gökçedağ

https://doi.org/10.54005/geneltip.1524630

Abstract

ABSTRACT

Background/Aims: The relationship between vitamin D and schizophrenia has been the focus of studies in the last 20 years. Studies have shown that approximately 65% of schizophrenia patients have vitamin D deficiency. This study aimed to retrospectively investigate the vitamin D levels of schizophrenia and schizoaffective disorder (SAD) patients receiving inpatient treatment at a tertiary care hospital.

Material and Methods: Patients diagnosed with Schizophrenia and SAD who received inpatient treatment at the psychosis service of a tertiary care hospital in the last two years (2021-2023) were included in this study. The data of 230 patients were examined retrospectively from hospital and file records.

Results: Among the patients in the study, 47.8% were female with a mean age of 42.3±15.8 years, and 52.2% were male with a mean age of 37.2±14.1 years. Among women, 24.5% had SAD and 75.5% had schizophrenia, among men, 30.8% had SAD and 69.2% had schizophrenia. Vitamin D deficiency was found in 73% of the group, vitamin D insufficiency was found in 17.4%, and normal vitamin D levels were found in 9.6%. No statistically significant relationship was found when vitamin D levels were compared between male and female patient groups (p = 0.068). When vitamin D levels were compared between patient groups diagnosed with schizophrenia and SAD, no statistically significant relationship was found. (p>0.05)

Conclusion:
Despite advances in the treatment of schizophrenia, these advances are insufficient to reduce the morbidity and mortality of the disease, so prophylactic measures should be explored. Adequate D vitamin supplementation during critical stages of life, including pregnancy, may be a meaningful, simple, safe, and cost-effective intervention.

Keywords

schizoaffective disorder, schizophrenia, vitamin D deficiency, vitamin D insufficiency, retrospective study

Ethical Statement

This research was approved by The Pamukkale University Non-Interventional Clinical Research Ethics Committee with decision number 05 dated 05.03.2023.

References

• 1. AlGhamdi SA. Effectiveness of Vitamin D on Neurological and Mental Disorders. Diseases 2024;12(6):131
• 2. Jahorkowski P, Hindley GFL, Shadrin AA, Tesfaye M, Bahrami S, Nerhus M, et al. Genome-wide Association Analysis of Schizophrenia and Vitamin D Levels Shows Shared Genetic Architecture and Identifies Novel Risk Loci. Schizophr Bull 2023;49(6):1654-1664.
• 3. Öncül Börekçi N. Current information on vitamin D deficiency. Jour Turk Fam Phy 2019; 10 (1): 35-42. doi: 10.15511/jtfp.19.00135
• 4. Goh XX, Tee SF, Tang PY, Chee KY, Loh KKW. Impact of body mass index elevation, Vitamin D receptor polymorphisms and antipsychotics on the risk of Vitamin D deficiency in schizophrenia patients. J Psychiatr Res 2024;175:350-358. doi: 10.1016/j.jpsychires.2024.05.005.
• 5. Demirkol ME, Tamam L, Çakmak S, Yeşiloğlu C. The relationship between metabolic syndrome and vitamin D levels in patients with schizophrenia. Cukurova Medical Journal 2019;44(3):1110-1117.
• 6. Boerman R, Cohen D, Schulte PF, Nugter A. Prevalence of Vitamin D Deficiency in Adult Outpatients with Bipolar Disorder or Schizophrenia. J Clin Psychopharmacol 2016;36(6):588-592.
• 7. Fond G, Faugere M, Faget-Agius C, Cermolacce M, Richieri R, Boyer L, et al. Hypovitaminosis D is associated with negative symptoms, suicide risk, agoraphobia, impaired functional remission, and antidepressant consumption in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2019;269(8):879-886.doi:10.1007/s00406-018-0932-0.
• 8. Puşuroğlu M, Baltacıoğlu M, Helvacı Çelik F, Bahceci B, Hocaoglu C. Relationship Between Serum Vitamin D Levels And Suicide Thought In Patients With Schizophrenia. Medical Journal of Ankara Training and Research Hospital 2022;55(2):138-142.
• 9. Siddique JA, Quereshi SF, Shawosh YA. Role of Vitamin D in schizophrenia in elderly patient. Journal of Geriatric Mental Health 2018;5:65-67.
• 10. Tolppanen AM, Sayers A, Fraser WD, Lewis G, Zammit S, Mcgrath J, et al. Serum 25-hydroxyvitamin D3 and D2 and non-clinical psychotic experiences in childhood. PLoS One 2012;7:e41575
• 11. Tsiglopoulos J, Pearson N, Mifsud N, Castagnini E, Allott K, Thompson A, et al. The prevalence of vitamin D deficiency and associated factors in first-episode psychosis. Early Interv Psychiatry 2024;18(3):237-242. doi: 10.1111/eip.13465.
• 12. Belzeaux R, Boyer L, Ibrahim EC, Féron F, Leboyer M, Fond G. Mood disorders are associated with a more severe hypovitaminosis D than schizophrenia. Psychiatry Res 2015;229(1-2):613-616. doi: 10.1016/j.psychres.2015.04.039.
• 13. Zhu JL, Luo WW, Cheng X, Li Y, Zhang QZ, Peng WX. Vitamin D deficiency and Schizophrenia in Adults: A Systematic Review and Meta-analysis of Observational Studies. Psychiatry Res 2020;288:112959. doi: 10.1016/j.psychres.2020.112959.
• 14. Ling C, Sun L, Luo B, Yu H, Li W, Yang Y,et al. Association of bone turnover markers and cognitive function in Chinese chronic schizophrenia patients with or without vitamin D insufficiency. BMC Psychiatry 2023;23(1):867.
• 15. Baltacıoğlu M, Puşuroğlu M, Bahceci B, Hocaoglu C, Helvacı Celik FG. Evolation of the relationship of vitamin D levels with psychotic and depressive symptoms in patients with schizophrenia. Akd Med J 2024; 10(1): 84-91.
• 16. Çubukçu M, Acı R, Müderrisoğlu S. Evaluation of Vitamin D Levels According to Age, Sex and Seasonal Characteristics in Samsun. Ankara Med J 2019;(4):769-775.
• 17. Telo S. Alteration of Vitamin D Levels According to Age, Gender and Seasons in Elazığ. Fırat Med J 2017; 22(1): 29 - 33.
• 18. Neriman A, Hakan Y, Ozge U. The psychotropic effect of vitamin D supplementation on schizophrenia symptoms. BMC Psychiatry 2021;21(1):309. doi: 10.1186/s12888-021-03308-w.
• 19. Kalejahi P, Kheirouri S, Noorazar SG. A randomized controlled trial of Vitamin D supplementation in Iranian patients with schizophrenia: Effects on serum levels of glycogen synthase kinase-3β and symptom severity. Int J Psychiatry Med 2023;58(6):559-575. doi: 10.1177/00912174231193303.
• 20. Lally J, Ajnakina O, Singh N, Gardner-Sood P, Stubbs B, Stringer D, et al. Vitamin D and clinical symptoms in First Episode Psychosis (FEP): A prospective cohort study. Schizophr Res 2019;204:381-388. doi: 10.1016/j.schres.2018.08.011.